Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11524053
Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
granted -
US 11525002
Human PD-L1 antibodies and methods of use therefor
granted -
US 11524063
Materials and methods relating to immunogenic epitopes from human papillomavirus
granted -
US 11518800
Mutations that drive VH4 antibody autoreactivity
granted -
US 11518818
Therapeutic anti-IgE antibodies and methods and compositions thereof
granted -
US 11517633
Production of Lu-177 and other radionuclides via hot atom capture on nanostructured carbon
granted -
US 11519007
Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
granted -
US 11518785
Peptide showing melanogenesis promoting activity and use thereof
granted -
US 11512112
Peptide for suppressing osteoclast differentiation and use thereof
granted -
US 11510880
Compositions and methods for organ specific delivery of nucleic acids
granted -
US 11512312
Treatment of Fuchs' endothelial corneal dystrophy
granted -
US 11510929
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
granted -
US 11510996
Covalent polymer-antigen conjugated particles
granted -
US 11512141
Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
granted -
US 11503999
Hyperspectral imaging for detection of Alzheimer's disease
granted -
US 11505798
Methods and compositions for treating inflammatory diseases
granted -
US 11504325
Micelles and vesicles for the delivery of glycopeptides
granted -
US 11505585
FcRn antagonists and methods of use
granted -
US 11505598
Antibodies to botulinum neurotoxins
granted -
US 11504427
Acoustic and ultrasound-based mechanogenetics and thermogenetics for immunotherapy
granted -
US 11505572
Therapeutics for the treatment of glaucoma
granted -
US 11504346
Redox-activated pro-chelators
granted -
US 11505574
Modulation of P53 for the treatment of cancer
granted -
US 11504394
Targeted ionophore-based metal delivery
granted -
US 11498928
Macrocyclic spiroethers as Mcl-1 inhibitors
granted -
US 11498963
Anti-LILRB antibodies and their use in detecting and treating cancer
granted -
US 11497740
Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer
granted -
US 11497770
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
granted -
US 11498905
Inhibitors of platelet function and methods for use of the same
granted -
US 11492604
Transposase polypeptides and uses thereof
granted -
US 11492406
Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
granted -
US 11492368
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
granted -
US 11491184
Liquids rich in noble gas and methods of their preparation and use
granted -
US 11491215
Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems
granted -
US 11492650
Production of seleno-biologics in genomically recoded organisms
granted -
US 11491111
Thermostable vaccine compositions and methods of preparing same
granted -
US 11491115
Nanoparticles containing extracellular matrix for drug delivery
granted -
US 11484581
Method to create personalized canine cancer vaccines
granted -
US 11485760
Inhibitors of CRISPR-Cas9
granted -
US 11485758
Bi-terminal pegylated integrin-binding peptides and methods of use thereof
granted -
US 11484545
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 11484591
Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
granted -
US 11484521
Antidotes to cyanide poisoning
granted -
US 11484525
Mu opioid receptor modulators
granted -
US 11484603
Methods, systems, and compositions for inhibiting virulence of A/E family pathogens
granted -
US 11485961
Compositions and methods for treating celiac sprue disease
granted -
US 11478517
Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof
granted -
US 11479601
Antibodies specific to Sonic Hedgehog and method of use thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory